The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Fenofibrate Market Research Report 2024
Synopsis
Fenofibrate, marketed as Tricor and under several other brand names, is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.
The global Fenofibrate market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Fenofibrate is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Fenofibrate is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Fenofibrate include AbbVie, Lupin, Salix Pharmaceuticals, Vectura, Cipher Pharmaceuticals, Rhodes Pharmaceuticals, Impax Laboratories, Mylan and Teva, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Fenofibrate, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fenofibrate.
Report Scope
The Fenofibrate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Fenofibrate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Fenofibrate manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Lupin
Salix Pharmaceuticals
Vectura
Cipher Pharmaceuticals
Rhodes Pharmaceuticals
Impax Laboratories
Mylan
Teva
Sun Pharmaceutical
Bausch Health
HETERO
Aurobindo Pharma
Cipla
Amneal Pharmaceuticals
Prinston Pharmaceutical
Dr. Reddys Laboratories
APOTEX
Glenmark
Segment by Type
Tablet
Capsule
Segment by Application
Hospital
Drug Store
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Fenofibrate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Fenofibrate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Fenofibrate, marketed as Tricor and under several other brand names, is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.
The global Fenofibrate market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Fenofibrate is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Fenofibrate is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Fenofibrate include AbbVie, Lupin, Salix Pharmaceuticals, Vectura, Cipher Pharmaceuticals, Rhodes Pharmaceuticals, Impax Laboratories, Mylan and Teva, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Fenofibrate, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fenofibrate.
Report Scope
The Fenofibrate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Fenofibrate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Fenofibrate manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Lupin
Salix Pharmaceuticals
Vectura
Cipher Pharmaceuticals
Rhodes Pharmaceuticals
Impax Laboratories
Mylan
Teva
Sun Pharmaceutical
Bausch Health
HETERO
Aurobindo Pharma
Cipla
Amneal Pharmaceuticals
Prinston Pharmaceutical
Dr. Reddys Laboratories
APOTEX
Glenmark
Segment by Type
Tablet
Capsule
Segment by Application
Hospital
Drug Store
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Fenofibrate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Fenofibrate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Fenofibrate Market Overview
1.1 Product Overview and Scope of Fenofibrate
1.2 Fenofibrate Segment by Type
1.2.1 Global Fenofibrate Market Value Comparison by Type (2024-2030)
1.2.2 Tablet
1.2.3 Capsule
1.3 Fenofibrate Segment by Application
1.3.1 Global Fenofibrate Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Drug Store
1.4 Global Fenofibrate Market Size Estimates and Forecasts
1.4.1 Global Fenofibrate Revenue 2019-2030
1.4.2 Global Fenofibrate Sales 2019-2030
1.4.3 Global Fenofibrate Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Fenofibrate Market Competition by Manufacturers
2.1 Global Fenofibrate Sales Market Share by Manufacturers (2019-2024)
2.2 Global Fenofibrate Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Fenofibrate Average Price by Manufacturers (2019-2024)
2.4 Global Fenofibrate Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Fenofibrate, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Fenofibrate, Product Type & Application
2.7 Fenofibrate Market Competitive Situation and Trends
2.7.1 Fenofibrate Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Fenofibrate Players Market Share by Revenue
2.7.3 Global Fenofibrate Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Fenofibrate Retrospective Market Scenario by Region
3.1 Global Fenofibrate Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Fenofibrate Global Fenofibrate Sales by Region: 2019-2030
3.2.1 Global Fenofibrate Sales by Region: 2019-2024
3.2.2 Global Fenofibrate Sales by Region: 2025-2030
3.3 Global Fenofibrate Global Fenofibrate Revenue by Region: 2019-2030
3.3.1 Global Fenofibrate Revenue by Region: 2019-2024
3.3.2 Global Fenofibrate Revenue by Region: 2025-2030
3.4 North America Fenofibrate Market Facts & Figures by Country
3.4.1 North America Fenofibrate Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Fenofibrate Sales by Country (2019-2030)
3.4.3 North America Fenofibrate Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Fenofibrate Market Facts & Figures by Country
3.5.1 Europe Fenofibrate Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Fenofibrate Sales by Country (2019-2030)
3.5.3 Europe Fenofibrate Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Fenofibrate Market Facts & Figures by Country
3.6.1 Asia Pacific Fenofibrate Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Fenofibrate Sales by Country (2019-2030)
3.6.3 Asia Pacific Fenofibrate Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Fenofibrate Market Facts & Figures by Country
3.7.1 Latin America Fenofibrate Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Fenofibrate Sales by Country (2019-2030)
3.7.3 Latin America Fenofibrate Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Fenofibrate Market Facts & Figures by Country
3.8.1 Middle East and Africa Fenofibrate Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Fenofibrate Sales by Country (2019-2030)
3.8.3 Middle East and Africa Fenofibrate Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Fenofibrate Sales by Type (2019-2030)
4.1.1 Global Fenofibrate Sales by Type (2019-2024)
4.1.2 Global Fenofibrate Sales by Type (2025-2030)
4.1.3 Global Fenofibrate Sales Market Share by Type (2019-2030)
4.2 Global Fenofibrate Revenue by Type (2019-2030)
4.2.1 Global Fenofibrate Revenue by Type (2019-2024)
4.2.2 Global Fenofibrate Revenue by Type (2025-2030)
4.2.3 Global Fenofibrate Revenue Market Share by Type (2019-2030)
4.3 Global Fenofibrate Price by Type (2019-2030)
5 Segment by Application
5.1 Global Fenofibrate Sales by Application (2019-2030)
5.1.1 Global Fenofibrate Sales by Application (2019-2024)
5.1.2 Global Fenofibrate Sales by Application (2025-2030)
5.1.3 Global Fenofibrate Sales Market Share by Application (2019-2030)
5.2 Global Fenofibrate Revenue by Application (2019-2030)
5.2.1 Global Fenofibrate Revenue by Application (2019-2024)
5.2.2 Global Fenofibrate Revenue by Application (2025-2030)
5.2.3 Global Fenofibrate Revenue Market Share by Application (2019-2030)
5.3 Global Fenofibrate Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Corporation Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AbbVie Fenofibrate Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Lupin
6.2.1 Lupin Corporation Information
6.2.2 Lupin Description and Business Overview
6.2.3 Lupin Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Lupin Fenofibrate Product Portfolio
6.2.5 Lupin Recent Developments/Updates
6.3 Salix Pharmaceuticals
6.3.1 Salix Pharmaceuticals Corporation Information
6.3.2 Salix Pharmaceuticals Description and Business Overview
6.3.3 Salix Pharmaceuticals Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Salix Pharmaceuticals Fenofibrate Product Portfolio
6.3.5 Salix Pharmaceuticals Recent Developments/Updates
6.4 Vectura
6.4.1 Vectura Corporation Information
6.4.2 Vectura Description and Business Overview
6.4.3 Vectura Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Vectura Fenofibrate Product Portfolio
6.4.5 Vectura Recent Developments/Updates
6.5 Cipher Pharmaceuticals
6.5.1 Cipher Pharmaceuticals Corporation Information
6.5.2 Cipher Pharmaceuticals Description and Business Overview
6.5.3 Cipher Pharmaceuticals Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Cipher Pharmaceuticals Fenofibrate Product Portfolio
6.5.5 Cipher Pharmaceuticals Recent Developments/Updates
6.6 Rhodes Pharmaceuticals
6.6.1 Rhodes Pharmaceuticals Corporation Information
6.6.2 Rhodes Pharmaceuticals Description and Business Overview
6.6.3 Rhodes Pharmaceuticals Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Rhodes Pharmaceuticals Fenofibrate Product Portfolio
6.6.5 Rhodes Pharmaceuticals Recent Developments/Updates
6.7 Impax Laboratories
6.6.1 Impax Laboratories Corporation Information
6.6.2 Impax Laboratories Description and Business Overview
6.6.3 Impax Laboratories Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Impax Laboratories Fenofibrate Product Portfolio
6.7.5 Impax Laboratories Recent Developments/Updates
6.8 Mylan
6.8.1 Mylan Corporation Information
6.8.2 Mylan Description and Business Overview
6.8.3 Mylan Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Mylan Fenofibrate Product Portfolio
6.8.5 Mylan Recent Developments/Updates
6.9 Teva
6.9.1 Teva Corporation Information
6.9.2 Teva Description and Business Overview
6.9.3 Teva Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Teva Fenofibrate Product Portfolio
6.9.5 Teva Recent Developments/Updates
6.10 Sun Pharmaceutical
6.10.1 Sun Pharmaceutical Corporation Information
6.10.2 Sun Pharmaceutical Description and Business Overview
6.10.3 Sun Pharmaceutical Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Sun Pharmaceutical Fenofibrate Product Portfolio
6.10.5 Sun Pharmaceutical Recent Developments/Updates
6.11 Bausch Health
6.11.1 Bausch Health Corporation Information
6.11.2 Bausch Health Fenofibrate Description and Business Overview
6.11.3 Bausch Health Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Bausch Health Fenofibrate Product Portfolio
6.11.5 Bausch Health Recent Developments/Updates
6.12 HETERO
6.12.1 HETERO Corporation Information
6.12.2 HETERO Fenofibrate Description and Business Overview
6.12.3 HETERO Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.12.4 HETERO Fenofibrate Product Portfolio
6.12.5 HETERO Recent Developments/Updates
6.13 Aurobindo Pharma
6.13.1 Aurobindo Pharma Corporation Information
6.13.2 Aurobindo Pharma Fenofibrate Description and Business Overview
6.13.3 Aurobindo Pharma Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Aurobindo Pharma Fenofibrate Product Portfolio
6.13.5 Aurobindo Pharma Recent Developments/Updates
6.14 Cipla
6.14.1 Cipla Corporation Information
6.14.2 Cipla Fenofibrate Description and Business Overview
6.14.3 Cipla Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Cipla Fenofibrate Product Portfolio
6.14.5 Cipla Recent Developments/Updates
6.15 Amneal Pharmaceuticals
6.15.1 Amneal Pharmaceuticals Corporation Information
6.15.2 Amneal Pharmaceuticals Fenofibrate Description and Business Overview
6.15.3 Amneal Pharmaceuticals Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Amneal Pharmaceuticals Fenofibrate Product Portfolio
6.15.5 Amneal Pharmaceuticals Recent Developments/Updates
6.16 Prinston Pharmaceutical
6.16.1 Prinston Pharmaceutical Corporation Information
6.16.2 Prinston Pharmaceutical Fenofibrate Description and Business Overview
6.16.3 Prinston Pharmaceutical Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Prinston Pharmaceutical Fenofibrate Product Portfolio
6.16.5 Prinston Pharmaceutical Recent Developments/Updates
6.17 Dr. Reddys Laboratories
6.17.1 Dr. Reddys Laboratories Corporation Information
6.17.2 Dr. Reddys Laboratories Fenofibrate Description and Business Overview
6.17.3 Dr. Reddys Laboratories Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Dr. Reddys Laboratories Fenofibrate Product Portfolio
6.17.5 Dr. Reddys Laboratories Recent Developments/Updates
6.18 APOTEX
6.18.1 APOTEX Corporation Information
6.18.2 APOTEX Fenofibrate Description and Business Overview
6.18.3 APOTEX Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.18.4 APOTEX Fenofibrate Product Portfolio
6.18.5 APOTEX Recent Developments/Updates
6.19 Glenmark
6.19.1 Glenmark Corporation Information
6.19.2 Glenmark Fenofibrate Description and Business Overview
6.19.3 Glenmark Fenofibrate Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Glenmark Fenofibrate Product Portfolio
6.19.5 Glenmark Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Fenofibrate Industry Chain Analysis
7.2 Fenofibrate Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Fenofibrate Production Mode & Process
7.4 Fenofibrate Sales and Marketing
7.4.1 Fenofibrate Sales Channels
7.4.2 Fenofibrate Distributors
7.5 Fenofibrate Customers
8 Fenofibrate Market Dynamics
8.1 Fenofibrate Industry Trends
8.2 Fenofibrate Market Drivers
8.3 Fenofibrate Market Challenges
8.4 Fenofibrate Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
